Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del (LIGHT-CF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02653027|
Recruitment Status : Withdrawn (Potential subjects were already on the combination therapy.)
First Posted : January 12, 2016
Last Update Posted : July 31, 2019
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Cystic Fibrosis||Drug: Lumacaftor-ivacaftor Other: OGTT||Not Applicable|
This is a single center, open label study with crossover in patients with Cystic Fibrosis (CF). Patients will have 2-3 visits at the Diabetes Center at Massachusetts General Hospital (MGH).
The participants will have been previously screened clinically to make sure they are candidates for starting the combination drug, lumacaftor-ivacaftor. These patients will be contacted prior to their first visit to discuss enrollment in the study.
At the first study visit (Visit 1), the participant will come to the Diabetes Center after an overnight fast of at least 8 hours. The following will occur at this study visit: informed consent; brief medical history; weight and height; vital signs and blood pressure; blood draw for DNA extraction, and an extra research tube for storage; administration of 75g Glucola load as per a standard oral glucose tolerance test (OGTT) protocol; and blood work for glucose and insulin at 30, 60, 90 and 120 minutes after the glucose load. This will be scheduled at a time that is convenient to the patient, with an attempt to coordinate with the patient's visit to the CF clinic prior to starting lumacaftor-ivacaftor combination drug.
At the 2nd study visit (Visit 2), which will take place 3 months after starting the combination drug, the participant will again come to the Diabetes Center after an overnight fast of at least 8 hours. The participant will undergo a second OGTT as in the first visit. The 3rd study visit (Visit 3) will be 6 months after initiation of the drug, and will have a repeat administration of an OGTT. If a participant starts the combination drug before enrolling in the study, he/she can still participate in the study as long as he or she has had a clinical OGTT performed within 6 months of starting the combination drug. In these cases, the informed consent, brief medical history, weight and height and vital signs and blood pressure, as well as blood draw for DNA will occur on the Visit 2, which will be the first study visit for these participants. If a clinical OGTT had been performed prior to but within 6 months of starting the combination therapy, this OGTT can be used in analysis of the data, although will not have the full amount of data as the study OGTT.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Study of the Effect of Combination Lumacaftor and Ivacaftor on Glucose Tolerance in Persons With Cystic Fibrosis Who Are Homozygous for the Phe508del Cystic Fibrosis Transmembrane Conductance Regulator Mutation.|
|Actual Study Start Date :||January 1, 2018|
|Estimated Primary Completion Date :||February 1, 2018|
|Actual Study Completion Date :||May 1, 2018|
Experimental: Lumacaftor Ivacaftor
Subjects will get an OGTT before and after starting the combination therapy lumacaftor-ivacaftor.
Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.
Other Name: Orkambi
A subject is given an oral glucose load and insulin and glucose measurements are taken at specified time periods.
Other Name: Oral Glucose tolerance test
- Change in Fasting Glucose [ Time Frame: 3 months ]This will be compared from baseline to 3 months after starting the medication
- Change in Fasting Glucose [ Time Frame: 6 months ]This will compare baseline to 6 months after starting the medication
- Genetic risk score [ Time Frame: 6 months ]We will examine how the OGTT data is dependent on genotype at variants associated with type 2 diabetes using a genetic risk score
- Pulmonary function test (PFT) FEV1 measurements [ Time Frame: 6 months ]We will compare how PFT measurement of FEV1 are related to changes in OGTT
- Change in Fasting Insulin [ Time Frame: 3 months ]This will be compared from baseline to 3 months after starting the medication
- Change in Fasting Insulin [ Time Frame: 6 months ]This will be compared from baseline to 6 months after starting the medication
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02653027
|Principal Investigator:||Jose Florez, MD, PhD||Massachusetts General Hospital|